Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents.

Chuanzhen CaoXiaomei LanBingqing ShangWeixing JiangLei GuoShan ZhengXingang BiAiping ZhouZhijian SunJian-Zhong Shou

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)

We established and validated organoids derived from tissues dissected from a patient with metastatic tRCC with PRCC-TFE3 fusion and achieved the HTS process for the first time. Crizotinib might be a targeted therapy worthy of exploration in the clinic for metastatic tRCC with PRCC-TFE3 fusion. Such organoid and HTS assays may represent a promising model system in translational research assisting in the development of clinical strategies.

Keyphrases

squamous cell carcinoma
small cell lung cancer
renal cell carcinoma
gene expression
primary care
case report
high throughput
advanced non small cell lung cancer
single cell
epidermal growth factor receptor
tyrosine kinase